AI-powered HER2 test study for bladder cancer patients
Part of Cancer clinical trials.
This study uses artificial intelligence to examine MRI scans and tissue samples to understand HER2 protein levels in urothelial carcinoma. It aims to improve how HER2 is assessed, which could guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with urothelial carcinoma (a type of bladder or urinary tract cancer).
- You have an MRI scan done before your biopsy or surgery that can be used for this study.
- Your tumor tissue (paraffin-embedded block) and digital images of it are available.
- Your HER2 status has already been checked using a standard lab test (immunohistochemistry).
- You have signed a consent form agreeing to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
This study is testing whether artificial intelligence can better predict prostate cancer by combining two types of scans (MRI and PSMA PET) along with your medical history, PSA, and biopsy results. If you have already had these scans and a biopsy, your information may help researchers develop a more accurate, non-invasive diagnostic tool.
This study uses ultrasound with AI to better diagnose bladder masses. It's for people who have a suspicious finding on a bladder ultrasound and are already planning to have surgery to treat it.
This trial tests if artificial intelligence can spot bladder tumors in videos taken during a cystoscopy exam. If you are already scheduled for a cystoscopy and the video is clear, you may be able to participate.
This trial uses an artificial intelligence model to analyze CT scans taken before bladder removal surgery. The goal is to see if the AI can predict outcomes for patients with muscle-invasive bladder cancer.
This trial tests an artificial-intelligence (AI) tool that uses your bladder cancer details to help predict outcomes. It may help doctors better choose the next treatment after bladder cancer is found early (non-muscle invasive).
Hear when a new HER2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.